Igc-501, Igc-502 And Igc-503 Are Novel Combination Therapies That, If Proven Out By Clinical Trials, Are Expected To Treat Pain, Medical Refractory Epilepsy And Eating Disorders Respectively, With Lower Side Effects Than Conventional Therapies.

IGC filed IGC-501 for a cannabis-based formulation to treat neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. India Globalization Capital also filed combination therapy formulations for the treatment of epilepsy/seizures (IGC-502) and cachexia (IGC-504). IGC-501, IGC-502 and IGC-503 are novel combination therapies that, if proven out by clinical trials, are expected to treat pain, medical refractory epilepsy and eating disorders respectively, with lower side effects than conventional therapies. Such ‘combination therapies’ have the unique opportunity to quickly move through the FDA’s approval process, since the drugs have already been individually approved. Consequently, IGC believes it has ‘first mover’ advantage in pursuing this approach to bring cannabis-based pharmaceutical products to market in a quick and cost-effective manner. The cannabis industry is growing in popularity. The wave of enthusiasm surrounding the recent legalization of cannabis in several new states is sweeping the country and IGC anticipates an explosion in demand for cannabinoid-based pharmaceutical therapies, technology, facilities and financial services. With a solid strategic plan in hand, this NYSE MKT listed company has a modest $9 million market capitalization which is just a fraction of their peer group, and is aggressively leaning on its connections to medical and procedural expertise to take advantage of one of many ground-floor opportunities. And, it is developing innovative therapies, while also acquiring technologies from related industries https://www.washingtonmedicalmarijuana.biz that will place it in the right position for capitalizing on its first-mover advantage.

To read more visit http://www.marketwatch.com/story/unique-cannabis-pharma-companies-trailblazing-the-medical-cannabis-industry-2017-03-16

Comments are closed.